ArticlePloS one2015
Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 4 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Differentially expressed microRNAs in human depression: a systematic review of case-control and longitudinal studies.BMC psychiatry · 2025Pooled it
- Identifying the differentially expressed peripheral blood microRNAs in psychiatric disorders: a systematic review and meta-analysis.Frontiers in psychiatry · 2024Pooled it
- A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis.International journal of molecular sciences · 2022Pooled it
- MicroRNAs expressed in depression and their associated pathways: A systematic review and a bioinformatics analysis.Journal of chemical neuroanatomy · 2019Pooled it
- Peripheral miRNA profiling identifies therapy-specific biological trajectories in the treatment of cognitive dysfunction in depression: an exploratory mechanistic study.Scientific reports · 2026Trial
- Trial
- MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study.International journal of molecular medicine · 2021Trial
- Macrophage Migration Inhibitory Factor and microRNA-451a in Response to Mindfulness-based Therapy or Treatment as Usual in Patients with Depression, Anxiety, or Stress and Adjustment Disorders.The international journal of neuropsychopharmacology · 2018Trial
- Exercise - induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects.Scientific reports · 2017Trial
- Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder.Medical science monitor : international medical journal of experimental and clinical research · 2016Trial
- Serum microRNAs for the assessment of symptomatically refractory gastroesophageal reflux disease despite acid suppression.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Plasma microRNA signatures in drug-naïve Romanian adolescents with first-episode psychosis.Frontiers in psychiatry · 2026Article
- GABAergic MicroRNA-34a in the Dorsal Raphe Nuclei Contributes to Circulating MicroRNA-34a Levels.Molecular neurobiology · 2025Article
- miRNA dysregulation in depression: unraveling the interplay between neuroplasticity, HPA axis dysfunction, and neuroinflammation.Metabolic brain disease · 2025Review
- Towards Objective Major Depressive Disorder Detection: a Systematic Review and Meta-Analysis of Diagnostic Biomarkers.The Psychiatric quarterly · 2025Review
- Plasma circulating microRNAs and symptoms of depression: Results from a population-based study.Psychiatry and clinical neurosciences · 2025Article
- Circulating miRNA Profile in Inflammatory Bowel Disease Patients with Stress, Anxiety, and Depression.International journal of molecular sciences · 2025Article
- The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023.Psychiatry investigation · 2025Article
- MicroRNA signatures in neuroplasticity, neuroinflammation and neurotransmission in association with depression.Journal of physiology and biochemistry · 2025Review
- LncRNA of peripheral blood mononuclear cells: HYMAI acts as a potential diagnostic and therapeutic biomarker for female major depressive disorder.Frontiers in psychiatry · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depression is a debilitating disease. To date, the development of biomarkers of major depressive disorder (MDD) remains a challenge. Recently, alterations in the expression of microRNAs (miRNAs) from post-mortem brain tissue and peripheral blood have been linked to MDD. The goals of this study were to detect the differential miRNAs in cerebrospinal fluid (CSF) and serum of MDD patients. First, the relative expression levels of 179 miRNAs (relative high levels in serum) were analyzed by miRNA PCR Panel in the CSF of MDD patients. Then, the differentially altered miRNAs from CSF were further assessed by qRT-PCR in the serum of the same patients. Finally, the serum differentially altered miRNAs were further validated by qRT-PCR in the serum of another MDD patients. The CSF-results indicated that 11 miRNAs in MDD patients were significantly higher than these in control subjects, and 5 miRNAs were significantly lower than these in control subjects. The serum-results from the same patients showed that 3 miRNAs (miR-221-3p, miR-34a-5p, and let-7d-3p) of the 11 miRNAs were significantly higher than these in control subjects, and 1 miRNA (miR-451a) of 5 miRNAs was significantly lower than these in control subjects. The up-regulation of miR-221-3p, miR-34a-5p, let-7d-3p and down-regulation of miR-451a was further validated in another 32 MDD patients. ROC analysis showed that the area under curve of let-7d-3p, miR-34a-5p, miR-221-3p and miR-451a was 0.94, 0.98, 0.97 and 0.94, with specificity of 90.48%, 95.24%, 90.48% and 90.48%, and sensitivity of 93.75%, 96.88%, 90.63% and 84.85%, respectively. In addition, target gene prediction found that the altered miRNAs are involved in affecting some important genes and pathway related to MDD. Our results suggested that differentially altered miRNAs in CSF might be involved in MDD, and serum miR-221-3p, miR-34a-5p, let-7d-3p, and miR-451a might be able to serve as biomarkers for MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.